Published in Infect Immun on July 01, 2000
Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun (2005) 1.14
Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol (2001) 1.02
Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun (2005) 0.93
Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I. Infect Immun (2006) 0.90
Host and bacterial factors affecting induction of immune responses to flagellin expressed by attenuated Salmonella vaccine strains. Infect Immun (2004) 0.89
Concomitant enterotoxigenic Escherichia coli infection induces increased immune responses to Vibrio cholerae O1 antigens in patients with cholera in Bangladesh. Infect Immun (2010) 0.86
Distinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration. Clin Vaccine Immunol (2011) 0.85
Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines. Infect Immun (2001) 0.82
Parenteral Adjuvant Effects of an Enterotoxigenic Escherichia coli Natural Heat-Labile Toxin Variant. Front Immunol (2014) 0.76
Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature (1981) 19.90
Purification and characterization of the CFA/I antigen of enterotoxigenic Escherichia coli. Infect Immun (1979) 4.24
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine (1988) 3.00
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A (1995) 2.63
The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol (1992) 2.52
Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J Immunol (1996) 2.30
Presence of colonization factor antigens on fresh isolates of fecal Escherichia coli: a prospective study. J Infect Dis (1985) 1.87
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J Infect Dis (1997) 1.51
The mechanism of cholera toxin adjuvanticity. Res Immunol (1998) 1.51
The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand J Immunol (1991) 1.51
Cholera toxin and its subunits as potential oral adjuvants. Curr Top Microbiol Immunol (1989) 1.43
Administration of purified colonization factor antigens (CFA/I, CFA/II) of enterotoxigenic Escherichia coli to volunteers. Response to challenge with virulent enterotoxigenic Escherichia coli. Gastroenterology (1984) 1.38
Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol (1994) 1.34
Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits. Infect Immun (1997) 1.27
Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers. Vaccine (1994) 1.20
Analysis of colonization factor antigen I, an adhesin of enterotoxigenic Escherichia coli O78:H11: fimbrial morphology and location of the receptor-binding site. Infect Immun (1991) 1.18
Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine (1993) 1.17
Molecular cloning and nucleotide sequence of the colonization factor antigen I gene of Escherichia coli. Infect Immun (1989) 1.15
Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect Immun (1997) 1.13
In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae. Infect Immun (1999) 1.08
A conserved residue in the tip proteins of CS1 and CFA/I pili of enterotoxigenic Escherichia coli that is essential for adherence. Proc Natl Acad Sci U S A (1999) 1.07
Levels of expression and immunogenicity of attenuated Salmonella enterica serovar typhimurium strains expressing Escherichia coli mutant heat-labile enterotoxin. Infect Immun (1998) 0.99
Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines. Infect Immun (1999) 0.92
Monoclonal antibodies against fimbrial subunits of colonization factor antigen I (CFA/I) inhibit binding to human enterocytes and protect against enterotoxigenic Escherichia coli expressing heterologous colonization factors. Microb Pathog (1996) 0.90
Identification of a cross-reactive continuous B-cell epitope in enterotoxigenic Escherichia coli colonization factor antigen I. Infect Immun (1996) 0.83
Immunization against the colonization factor antigen I of enterotoxigenic Escherichia coli by administration of a bivalent Salmonella typhimurium aroA strain. Braz J Med Biol Res (1998) 0.79
Cloning and expression of colonization factor antigen I (CFA/I) epitopes of enterotoxigenic Escherichia coli (ETEC) in Salmonella flagellin. Res Microbiol (1998) 0.78
Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect Immun (1979) 7.21
Nonuniform probability of glutamate release at a hippocampal synapse. Science (1993) 4.23
Vibrio cholerae adherence and colonization in experimental cholera: electron microscopic studies. Infect Immun (1976) 4.03
Immunological cross-reactivity between a heat-labile enterotoxin(s) of Escherichia coli and subunits of Vibrio cholerae enterotoxin. Infect Immun (1978) 3.95
Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect Immun (1978) 3.80
Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun (1980) 3.36
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Subunit number and arrangement in Escherichia coli heat-labile enterotoxin. Infect Immun (1981) 3.15
Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents. Nature (1990) 3.14
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol (2001) 3.05
Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science (1995) 2.44
Direct measurement of specific membrane capacitance in neurons. Biophys J (2000) 2.39
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med (1998) 2.20
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev (1992) 2.02
Mucosal adjuvants. Vaccine (2005) 1.86
Heteromeric AMPA receptors assemble with a preferred subunit stoichiometry and spatial arrangement. Neuron (2001) 1.72
Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immun (1984) 1.70
Immunological and physicochemical characterization of heat-labile enterotoxins isolated from two strains of Escherichia coli. Infect Immun (1982) 1.70
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Random amplification of polymorphic DNA reveals serotype-specific clonal clusters among enterotoxigenic Escherichia coli strains isolated from humans. J Clin Microbiol (1997) 1.66
Phylogenetic affiliation and ultrastructure of uncultured magnetic bacteria with unusually large magnetosomes. Arch Microbiol (1998) 1.64
Endogenous and exogenous interleukin-12 augment the protective immune response in mice orally challenged with Salmonella dublin. Infect Immun (1996) 1.60
Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol (2001) 1.59
Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine (1998) 1.58
Presynaptic glutamate receptors depress excitatory monosynaptic transmission between mouse hippocampal neurones. J Physiol (1990) 1.52
The role of transperineal ultrasonography in the assessment of the internal opening of cryptogenic anal fistula. Tech Coloproctol (2007) 1.48
Development of a vaccine of cross-linked heat-stable and heat-labile enterotoxins that protects against Escherichia coli producing either enterotoxin. Infect Immun (1982) 1.44
Effect of a purA mutation on efficacy of Salmonella live-vaccine vectors. Infect Immun (1989) 1.43
Oral immunization of mice with attenuated Salmonella enteritidis containing a recombinant plasmid which codes for production of the B subunit of heat-labile Escherichia coli enterotoxin. Infect Immun (1986) 1.43
Quantal amplitude and quantal variance of strontium-induced asynchronous EPSCs in rat dentate granule neurons. J Physiol (1999) 1.37
Arousal of mucosal secretory immunoglobulin A antitoxin in rats immunized with Escherichia coli heat-labile enterotoxin. Infect Immun (1982) 1.36
Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol (1998) 1.29
Vaccine for enterotoxigenic Escherichia coli based on synthetic heat-stable toxin crossed-linked to the B subunit of heat-labile toxin. J Infect Dis (1983) 1.29
The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine (1999) 1.28
Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun (1994) 1.25
In vivo induction of interleukin-12 mRNA expression after oral immunization with Salmonella dublin or the B subunit of Escherichia coli heat-labile enterotoxin. Infect Immun (1995) 1.24
Photolytic manipulation of [Ca2+]i reveals slow kinetics of potassium channels underlying the afterhyperpolarization in hippocampal pyramidal neurons. J Neurosci (1999) 1.23
Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers. Vaccine (1994) 1.20
Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J Virol (1999) 1.18
Nonuniform distribution of Ca2+ channel subtypes on presynaptic terminals of excitatory synapses in hippocampal cultures. J Neurosci (1997) 1.18
Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine (1993) 1.17
Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. Vaccine (1993) 1.17
Protection against human and porcine enterotoxigenic strains of Escherichia coli in rats immunized with a cross-linked toxoid vaccine. Infect Immun (1983) 1.17
Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers. Infect Immun (1991) 1.15
Control of the activity of the soluble lytic transglycosylase by the stringent response in Escherichia coli. FEMS Microbiol Lett (1990) 1.15
N- and P/Q-type Ca2+ channels mediate transmitter release with a similar cooperativity at rat hippocampal autapses. J Neurosci (1998) 1.15
Characterization of enterotoxigenic Escherichia coli by random amplification of polymorphic DNA. Res Microbiol (1996) 1.14
Protection in rats immunized with Escherichia coli heat-stable enterotoxin. Infect Immun (1981) 1.13
Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect Immun (1997) 1.13
Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J Immunol (2000) 1.13
Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol (1999) 1.13
Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect Immun (2001) 1.12
Immunization of rats with heat-labile enterotoxin provides uniform protection against heterologous serotypes of enterotoxigenic Escherichia coli. Infect Immun (1981) 1.11
Postsynaptic expression of long-term potentiation in the rat dentate gyrus demonstrated by variance-mean analysis. J Physiol (1999) 1.09
In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae. Infect Immun (1999) 1.08
Cloning and molecular characterization of the B subunit of Escherichia coli heat-labile enterotoxin. Infect Immun (1983) 1.06
Differential production of interleukin-12 mRNA by murine macrophages in response to viable or killed Salmonella spp. Infect Immun (1996) 1.05
[Enzootic paracoccidioidomycosis in armadillos (Dasypus novemcinctus) in the State of Pará]. Rev Inst Med Trop Sao Paulo (1986) 1.05
Degradation of trichlorophenols by Alcaligenes eutrophus JMP134. FEMS Microbiol Lett (1995) 1.04
Functional mapping of protective domains and epitopes in the rotavirus VP6 protein. J Virol (2000) 1.03
Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Clin Vaccine Immunol (2012) 1.02
Intracellular Salmonella dublin induces substantial secretion of the 40-kilodalton subunit of interleukin-12 (IL-12) but minimal secretion of IL-12 as a 70-kilodalton protein in murine macrophages. Infect Immun (1997) 1.02
Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol (2001) 1.02
Clonal nature of enterotoxigenic Escherichia coli serotype O6:H16 revealed by randomly amplified polymorphic DNA analysis. J Clin Microbiol (1998) 1.01
Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae. Mucosal Immunol (2011) 0.98
Intracellular tetraethylammonium ions enhance group Ia excitatory post-synaptic potentials evoked in cat motoneurones. J Physiol (1986) 0.97
Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen. Vaccine (1986) 0.97
Inactivation of the ampDE operon increases transcription of algD and affects morphology and encystment of Azotobacter vinelandii. J Bacteriol (2000) 0.96
Liposomes as vehicles for vaccines. Prog Clin Biol Res (1980) 0.96
Effects of mutating leucine to threonine in the M2 segment of alpha1 and beta1 subunits of GABAA alpha1beta1 receptors. J Membr Biol (1996) 0.95
Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine (2000) 0.95
Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect Immun (1999) 0.94
Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine (2001) 0.93
Development of mucosal protection against the heat-stable enterotoxin (ST) of Escherichia coli by oral immunization with a genetic fusion delivered by a bacterial vector. Infect Immun (1993) 0.92
Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Braz J Med Biol Res (1986) 0.92
Flagellin expressed by live Salmonella vaccine strains induces distinct antibody responses following delivery via systemic or mucosal immunization routes. FEMS Immunol Med Microbiol (2001) 0.91
Relationship between outer membrane protein and lipopolysaccharide profiles and serotypes of enterotoxigenic Escherichia coli isolated in Brazil. FEMS Microbiol Lett (1996) 0.90
Hypolipidaemic drugs are activated to acyl-CoA esters in isolated rat hepatocytes. Detection of drug activation by human liver homogenates and by human platelets. Biochem J (1992) 0.90
Long-term synaptic plasticity in the honeybee. J Neurophysiol (1997) 0.89
Intracellular distribution of heat-labile enterotoxin in a clinical isolate of Escherichia coli. Infect Immun (1985) 0.89
Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine (2002) 0.89
Beyond serotypes and virulence-associated factors: detection of genetic diversity among O153:H45 CFA/I heat-stable enterotoxigenic Escherichia coli strains. J Clin Microbiol (2001) 0.89
Antibody responses against flagellin in mice orally immunized with attenuated Salmonella vaccine strains. Arch Microbiol (1999) 0.88
Clonal relationships among Escherichia coli serogroup O6 isolates based on RAPD. FEMS Microbiol Lett (1997) 0.87
Contrasting definitive hosts as determinants of the genetic structure in a parasite with complex life cycle along the south-eastern Pacific. Mol Ecol (2015) 0.86
Mucosal T cells induce systemic anergy for oral tolerance. Biochem Biophys Res Commun (1995) 0.85
Local effects induced by venoms from five species of genus Micrurus sp. (coral snakes). Toxicon (1994) 0.85
Differences in cross-protection in rats immunized with the B subunits of cholera toxin and Escherichia coli heat-labile toxin. Infect Immun (1984) 0.85
Quantitative assessment of the synchronization of cell populations. J Gen Microbiol (1979) 0.84
Mutagenicity of CL 64855, a potent anti-Trypanosoma cruzi drug. Mutat Res (1986) 0.84
Altered expression of oligopeptide-binding protein (OppA) and aminoglycoside resistance in laboratory and clinical Escherichia coli strains. J Med Microbiol (2000) 0.84
Pentoxifylline may be useful in the treatment of type 2 leprosy reaction. Lepr Rev (1995) 0.83
Screening the mutagenic activities of commonly used antiparasite drugs by the Simultest, a simplified Salmonella/microsome plate incorporation assay. Rev Inst Med Trop Sao Paulo (1991) 0.83